Institut Català de la Salut
[Martín-Saladich Q, Hammawa K] Grup de Recerca d’Imatge Mèdica Molecular, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Unitat de Teràpia de Medicina Nuclear, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Servei de Radiodiagnòstic, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Bellaterra, Spain. Department of Information and Communication Technologies, Pompeu Fabra University, Barcelona, Spain. [Pareto D] Secció de Neuroradiologia, Servei de Radiodiagnòstic, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Institut Diagnòstic per la Imatge (IDI), Barcelona, Spain. Grup de Recerca de Neuroradiologia, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Simó R, Ciudin A] Grup de Recerca en Diabetis i Metabolisme, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei d’Endocrinologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Bellaterra, Spain. Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBER-DEM), Instituto de Salud Carlos III, Madrid, Spain. [Aparicio C, de la Calle Vargas E, Aguadé-Bruix S] Grup de Recerca d’Imatge Mèdica Molecular, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Unitat de Teràpia de Medicina Nuclear, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Servei de Radiodiagnòstic, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Bellaterra, Spain. [Giralt M, Ramirez-Serra C] Grup de Recerca de Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei de Bioquímica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Bellaterra, Spain. [Herance JR] Grup de Recerca d’Imatge Mèdica Molecular, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Unitat de Teràpia de Medicina Nuclear, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Servei de Radiodiagnòstic, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Bellaterra, Spain. Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanotecnología (CIBER-BBN), Instituto de Salud Carlos III, Madrid, Spain
Vall d'Hebron Barcelona Hospital Campus
2025-08-07T08:19:50Z
2025-08-07T08:19:50Z
2025
Brain function; Cognitive impairment; Insulin resistance
Funció cerebral; Deteriorament cognitiu; Resistència a la insulina
Función cerebral; Deterioro cognitivo; Resistencia a la insulina
Previous studies in patients without Type 2 diabetes suggest that brain hypo- and hypermetabolic regions may indicate risk for cognitive disorders. We aimed to study these brain glucose uptake patterns in Type 2 diabetes to assess cognitive disorder risk and improve personalized management. Six hyper- and three hypometabolic regions were obtained through statistical parametric mapping, with cerebellar vermis and right superior temporal gyrus being the most relevant areas, respectively. Such allowed identification of two phenotypes via k-means clustering: brain hypometabolic dominant (bU[−]) and hypermetabolic dominant (bU[+]). bU[−] displayed elevated markers of both Type 2 diabetes and cognitive disorders, specifically of secreted frizzled-related protein 1, a protein related to different neuronal pathologies. A classifier was developed (area under the curve = 0.84, true positive rate = 0.81 and true negative rate = 0.78) using a combination of biochemical features. Type 2 diabetes patients exhibit hypo- and hypermetabolic brain regions that phenotype into bU[−] and bU[+] by using the relationship between right superior temporal gyrus and cerebellar vermis, which defines the transition from one phenotype to the other. We suggest bU[−] patients are exposed to a higher risk of developing cognitive disorders based on the alteration of secreted frizzled-related protein 1 due to progressed type 2 diabetes, which can be identified using the proposed biomarker-based classification model.
This work was supported by the Carlos III Health Institute and the European Regional Development Fund (grant numbers: PI20/01588 and FI21/00304).
Article
Versió publicada
Anglès
Glucosa; Diabetis no-insulinodependent; Cervell - Imatgeria; Marcadors bioquímics; Fenotip; Deteriorament cognitiu lleu; Radiofàrmacs; CHEMICALS AND DRUGS::Carbohydrates::Sugars::Monosaccharides::Hexoses::Glucose; CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Diagnostic Uses of Chemicals::Radiopharmaceuticals; ANATOMY::Nervous System::Central Nervous System::Brain; Other subheadings::Other subheadings::Other subheadings::/diagnostic imaging; PHENOMENA AND PROCESSES::Genetic Phenomena::Phenotype; DISEASES::Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Diabetes Mellitus::Diabetes Mellitus, Type 2; PSYCHIATRY AND PSYCHOLOGY::Mental Disorders::Neurocognitive Disorders::Cognition Disorders::Cognitive Dysfunction; CHEMICALS AND DRUGS::Biological Factors::Biomarkers; COMPUESTOS QUÍMICOS Y DROGAS::hidratos de carbono::azúcares::monosacáridos::hexosas::glucosa; COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos diagnósticos de sustancias químicas::radiofármacos; ANATOMÍA::sistema nervioso::sistema nervioso central::encéfalo; Otros calificadores::Otros calificadores::Otros calificadores::/diagnóstico por imagen; FENÓMENOS Y PROCESOS::fenómenos genéticos::fenotipo; ENFERMEDADES::enfermedades nutricionales y metabólicas::enfermedades metabólicas::trastornos del metabolismo de la glucosa::diabetes mellitus::diabetes mellitus tipo II; PSIQUIATRÍA Y PSICOLOGÍA::trastornos mentales::trastornos neurocognitivos::trastornos cognitivos::disfunción cognitiva; COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::biomarcadores
Oxford University Press
Brain Communications;7(3)
https://doi.org/10.1093/braincomms/fcaf213
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Articles científics - VHIR [1655]